Original Article

You have full text access to this OnlineOpen article

The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy

  1. Isaac J. Powell M.D.,
  2. Susan J. Land Ph.D.,
  3. Jyotirmoy Dey Ph.D.,
  4. Lance K. Heilbrun Ph.D.,
  5. Mark R. Hughes M.D., Ph.D.,
  6. Wael Sakr M.D.,
  7. Richard B. Everson M.D., M.P.H.†,*

Article first published online: 3 JAN 2005

DOI: 10.1002/cncr.20788

Issue

Cancer

Cancer

Volume 103, Issue 3, pages 528–537, 1 February 2005

Additional Information

How to Cite

Powell, I. J., Land, S. J., Dey, J., Heilbrun, L. K., Hughes, M. R., Sakr, W. and Everson, R. B. (2005), The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer, 103: 528–537. doi: 10.1002/cncr.20788

Author Information

  1. Barbara Ann Karmanos Cancer Institute and Departments of Medicine and Pathology at Wayne State University School of Medicine, Detroit, Michigan

  1. †

    Fax: (313) 966-7368

*Barbara Ann Karmanos Cancer Institute, HWCRC Room 615, 110 East Warren Avenue, Detroit, MI 48201

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 3 JAN 2005
  3. Manuscript Accepted: 7 OCT 2004
  4. Manuscript Revised: 29 SEP 2004
  5. Manuscript Received: 4 MAY 2004

Funded by

  • National Institutes of Health/National Cancer Institute. Grant Numbers: CA81240, CA84989, CA22453
  • Michigan Life Sciences Corrider Fund (MLSCF). Grant Number: GR-473
  • Virtual Discovery Grant from the Barbara Ann Karmanos Cancer Institute at Wayne State University

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (230K)

REFERENCES

  • 1
    Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol. 1999; 26: 407–421.
  • 2
    Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992; 12: 241–253.
  • 3
    Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet. 1995; 4: 523–527.
  • 4
    Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994; 22: 3181–3186.
  • 5
    Coetzee GA, Ross RK. Re: prostate cancer and the androgen receptor. J Natl Cancer Inst. 1994; 86: 872–873.
  • 6
    Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995; 55: 1937–1940.
  • 7
    Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997; 89: 166–170.
  • 8
    Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA. 1997; 94: 3320–3323.
  • 9
    Stanford JL, Just JJ, Gibbs M, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 1997; 57: 1194–1198.
  • 10
    Montgomery JS, Price DK, Figg WD. The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol. 2001; 195: 138–146.
    Direct Link:
  • 11
    Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol. 2002; 12: 182–196.
  • 12
    Nelson KA, Witte JS. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol. 2002; 155: 883–890.
  • 13
    Giovannucci E. Is the androgen receptor CAG repeat length significant for prostate cancer? Cancer Epidemiol Biomarkers Prev. 2002; 11(10 Pt 1): 985–986.
  • 14
    Chen C, Lamharzi N, Weiss NS, et al. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002; 11(10 Pt 1): 1033–1040.
  • 15
    Nam RK, Elhaji Y, Krahn MD, et al. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol. 2000; 164: 567–572.
  • 16
    Edwards SM, Badzioch MD, Minter R, et al. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer. 1999; 84: 458–465.
    Direct Link:
  • 17
    Cude KJ, Montgomery JS, Price DK, et al. The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. Urol Int. 2002; 68: 16–23.
  • 18
    Powell IJ, Banerjee M, Sakr W, et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer. 1999; 85: 472–477.
    Direct Link:
  • 19
    Powell IJ, Dey J, Dudley A, et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology. 2002; 59: 907–912.
  • 20
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 24: 187–202.
  • 21
    Allison PD. Survival analysis using the SAS system: a practical guide. Cary: SAS Institute, Inc., 1995.
  • 22
    Bennett CL, Price DK, Kim S, et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002; 20: 3599–3604.
  • 23
    Kittles RA, Young D, Weinrich S, et al. Extent of linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in human populations: implications for prostate cancer risk. Hum Genet. 2001; 109: 253–261.
View Full Article (HTML) Get PDF (230K)